TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study

Reuters

06/04

TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study

TELA Bio, Inc., a commercial-stage medical technology company, has announced promising scientific research results for its OviTex Inguinal Reinforced Tissue Matrix. The product, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, has been launched in the European market following its successful introduction in the U.S., where it achieved over $1 million in sales in its first year. A retrospective study led by Dr. Paul Szotek from the Indiana Hernia Center examined the OviTex Core Permanent using the Reinforced Biologic Augmented Repair (ReBAR) technique in 259 patients. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years, highlighting the product's clinical efficacy. OviTex Inguinal is available in Europe in two configurations, designed for compatibility with laparoscopic and robotic procedures, and offers a naturally derived alternative to synthetic mesh for hernia repair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462686-en) on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540704131"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540704131\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540704131?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540704131","market":"nz","top_or_hot":-1,"title":"TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TELA\">TELA Bio, Inc.</a>, a commercial-stage medical technology company, has announced promising scientific research results for its OviTex Inguinal Reinforced Tissue Matrix. The product, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, has been launched in the European market following its successful introduction in the U.S., where it achieved over $1 million in sales in its first year. A retrospective study led by Dr. Paul Szotek from the Indiana Hernia Center examined the OviTex Core Permanent using the Reinforced Biologic Augmented Repair (ReBAR) technique in 259 patients. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years, highlighting the product's clinical efficacy. OviTex Inguinal is available in Europe in two configurations, designed for compatibility with laparoscopic and robotic procedures, and offers a naturally derived alternative to synthetic mesh for hernia repair.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462686-en) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-04 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TELA\">TELA Bio, Inc.</a>, a commercial-stage medical technology company, has announced promising scientific research results for its OviTex Inguinal Reinforced Tissue Matrix. The product, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, has been launched in the European market following its successful introduction in the U.S., where it achieved over $1 million in sales in its first year. A retrospective study led by Dr. Paul Szotek from the Indiana Hernia Center examined the OviTex Core Permanent using the Reinforced Biologic Augmented Repair (ReBAR) technique in 259 patients. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years, highlighting the product's clinical efficacy. OviTex Inguinal is available in Europe in two configurations, designed for compatibility with laparoscopic and robotic procedures, and offers a naturally derived alternative to synthetic mesh for hernia repair.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462686-en) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL1SF7cc:1","article_id":"2540704131","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540704131","pubTimestamp":1748981128,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TELA Bio, Inc., a commercial-stage medical technology company, has announced promising scientific research results for its OviTex Inguinal Reinforced Tissue Matrix. The product, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, has been launched in the European market following its successful introduction in the U.S., where it achieved over $1 million in sales in its first year. A retrospective study led by Dr. Paul Szotek from the Indiana Hernia Center examined the OviTex Core Permanent using the Reinforced Biologic Augmented Repair  technique in 259 patients. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years, highlighting the product's clinical efficacy. OviTex Inguinal is available in Europe in two configurations, designed for compatibility with laparoscopic and robotic procedures, and offers a naturally derived alternative to synthetic mesh for hernia repair.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4198":"医疗保健用品","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","TELA":"TELA Bio, Inc.","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"根据新研究，TELA Bio Inc.宣布使用OviTex Inguinal进行机器人腹股沟疝修补术的复发率为1.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TELA":0.9,"NDAQ":0.9},"content_text":"TELA Bio Inc. Announces Low 1.2% Recurrence Rate in Robotic Inguinal Hernia Repair with OviTex Inguinal, Based on New Study\n    \n\nTELA Bio, Inc., a commercial-stage medical technology company, has announced promising scientific research results for its OviTex Inguinal Reinforced Tissue Matrix. The product, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, has been launched in the European market following its successful introduction in the U.S., where it achieved over $1 million in sales in its first year. A retrospective study led by Dr. Paul Szotek from the Indiana Hernia Center examined the OviTex Core Permanent using the Reinforced Biologic Augmented Repair (ReBAR) technique in 259 patients. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years, highlighting the product's clinical efficacy. OviTex Inguinal is available in Europe in two configurations, designed for compatibility with laparoscopic and robotic procedures, and offers a naturally derived alternative to synthetic mesh for hernia repair.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462686-en) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}